Skip to main content
TOVX
NYSE Life Sciences

Theriva Posts Q3 Loss of $1.5M, Cash Runway Into Q1 2027

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Healthcare
Sentiment info
Negative
Importance info
7
Price
$0.16
Mkt Cap
$7.384M
52W Low
$0.136
52W High
$0.492
52W Position info
18% above low
Off High info
67% below high
Rel. Volume info
0.3× avg
Market data snapshot near publication time

TOVX sits 18% above its 52-week low of $0.136 on light trading volume (0.3× avg).

Summary

Theriva reported a $1.5 million third-quarter loss and $8.5 million in cash, enough to fund operations only into Q1 2027 — well short of the Q3 2027 VIRAGE2 data readout.


Key Events · Earnings and Guidance · TOVX

  • Q3 Loss Narrows to $1.5 Million

    For the three months ended September 30, 2026, net loss was $1.5 million, or $0.03 per share, versus $4.4 million, or $0.45 per share, a year earlier.

  • Cash Runway Only Into Q1 2027

    Cash and cash equivalents totaled $8.5 million at September 30, 2026, down $4.6 million from December 31, 2025, and fund operations only into Q1 2027.

  • VIRAGE2 Data Not Until Q3 2027

    Enrollment in the VIRAGE2 Phase 2a trial is expected to complete in Q4 2026, with initial pharmacodynamic and safety data anticipated by Q3 2027 — after the stated cash runway ends.

  • Biossil Deal Adds $350,000 Upfront

    The October 2026 sale of SYN-004, SYN-007 and SYN-006 to Biossil Labs closed with a $350,000 upfront payment plus up to $3 million in regulatory and up to $88 million in sales milestones and single-digit royalties capped at $250 million.


Analysis · TOVX · Life Sciences

Theriva ended September with $8.5 million in cash, and that funds operations only into Q1 2027 — roughly one quarter of runway for a company still enrolling the VIRAGE2 trial, whose initial data is not expected until Q3 2027. The gap makes another raise or a strategic transaction likely before the data read out, and the filing explicitly says the company continues to evaluate strategic alternatives. The quarter itself was leaner: net loss narrowed to $1.5 million from $4.4 million a year ago as G&A fell 51% and R&D fell 76% after the Phase 2b trial wound down. From the Biossil sale, only $350,000 comes upfront, with the up to $91 million in milestones back-end loaded and half of future milestone and royalty proceeds owed to PREV ABR up to $13 million.

How filings like this one have moved

In the 30 days to Nov 11, 2026, 36.6% of the 3434 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, TOVX was trading at $0.16 on NYSE in the Life Sciences sector, with a market capitalization of approximately $7.4M. The 52-week trading range was $0.14 to $0.49. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

TOVX - Latest Insights

TOVX
Nov 02, 2026, 4:05 PM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.1802
Real-time Price: $0.160 info
Change: -$0.0202 (-11%) info
Market Cap: $7.384M info